Lipid nanoparticles (LNPs)are delivery vehicles for currently two widely used mRNA COVID-19 vaccines. It has also shown good results in delivering genetic information to the liver. However, precise delivery of packaged goods into tissues other than the liver remains a challenge. Ina recent paperpublished recently in the Proceedings of the National Academy of Sciences (PNAS), Dr. Qiaobing Xu's group in the Department of Bioengineering at Tufts University, along with partners at Harvard Univer